Capivasertib is a pan-Akt small-molecule inhibitor of all three Akt isoforms approved for the treatment of ER/PR-positive BC that is also has either PIK3CA-mutated or Akt-altered or demonstrated PTEN-loss (Table 2) [102]. Here, PIK3CA is linked to breast cancer.